Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Leukaemia Drug Could Help Treat Breast Cancer

Published: Friday, August 23, 2013
Last Updated: Thursday, August 22, 2013
Bookmark and Share
A drug currently used to treat leukaemia might also help prevent breast cancer from spreading to other parts of the body.

The discovery could also pave the way for improved early diagnostics.

Peter Storz and colleagues tested the drug, decitabine, in a mouse model of breast cancer where it shrank the primary breast tumour and minimised metastasis to the animals' lungs. Mice treated with drug had very few or no metastases in their lungs, and those that were found were around 40 times smaller than those observed in untreated control animals. Decitabine, or drugs that work in a similar way, could be used to help manage breast cancer, the authors say, but human studies will be needed.

The drug works by targeting a particular gene, called PRKD1. Normally, the gene is switched on, but in invasive breast cancer, gene-inactivating molecules called methyl groups bind to the DNA next to the gene, switching it off. Decitabine prevents these methyl groups from binding to DNA.

Treatment with the drug reduced methylation levels around the PRKD1 gene. As a result, the gene was switched back on, and was able to start churning out protein as normal.

The authors also studied methylation levels in human breast cancer tissues with varying degrees of invasiveness. Methylation levels correlated with the cancer's potential to spread. The finding could, the authors say, be used to help generate a new diagnostic test that could predict how likely breast cancer is to metastasize.

Decitabine is one of a handful of FDA-approved cancer drugs that work via epigenetics, influencing the structure and form of DNA to affect gene expression, without altering the DNA sequence itself. Alongside genetic changes, epigenetic differences are now known to play a role in many different types of tumour, including prostate and cervical cancer. Decitabine is currently licensed for the treatment of acute myeloid leukaemia, a cancer of white blood cells.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Imaging Software Could Speed Up Breast Cancer Diagnosis
Researchers use high speed optical microscopy of intact breast tissue specimens to analyze breast tissue.
Friday, August 21, 2015
A Possible Blood Test for Alzheimer’s Disease
A new blood test can be used to discriminate between people with Alzheimer's disease and healthy controls.
Monday, July 29, 2013
Gene Signature Can Predict Who Will Survive Chemotherapy
An eight gene ‘signature’ can predict length of relapse-free survival after chemotherapy, finds new research in Biomed Central’s open access journal BMC Medicine.
Tuesday, April 16, 2013
Oxygen-Free Energy Designed to Fuel Brain Development Spurs on Growth of Cancer
The metabolic process which fuels the growth of many cancers has its origins in normal brain growth finds a new study published in BioMed Central's open access journal Cancer & Metabolism.
Wednesday, January 23, 2013
Genetic Predictor of Breast Cancer Response to Chemotherapy
Gene expression 'signatures' to measure the susceptibility of tumor cells to chemotherapy.
Friday, May 11, 2012
Cellular 'Glue' Resists Breast Cancer
New research demonstrates that the protein Perp provides a potential new target for future treatment of breast cancer.
Thursday, April 19, 2012
DIMming Cancer Growth - STAT: diindolylmethane Suppresses Ovarian Cancer
New research published in BioMed Central’s open access journal BMC Medicine has looked in detail at the action of DIM and showed that it works by blocking the activation and production of the transcription factor STAT3.
Wednesday, January 25, 2012
Relatives of Melanoma Patients Ignore their Skin Cancer Risk
New research shows that young people in ‘at risk’ group are still ignoring sun safety advice.
Thursday, December 29, 2011
Elevated Hormone Levels Add Up to Increased Breast Cancer Risk
New research found that the risk of breast cancer increased with the high levels of estrogen or testosterone hormones.
Monday, October 24, 2011
Modeling Cancer Using Ecological Principles
New research uses Tilman model of competition between invasive species to study the metastasis of prostate cells into bone.
Tuesday, October 04, 2011
Heart Disease Beats Breast Cancer as the Biggest Killer
Research shows that women with breast cancer died from other causes and that over the length of the study cardiovascular disease was the leading cause of death.
Tuesday, June 21, 2011
C-reactive Protein Levels Predict Breast Cancer Survival Rates
BioMed Central's new research shows that elevated CRP levels are predictive of a poor prognosis for breast cancer sufferers.
Friday, June 03, 2011
Coffee Reduces Breast Cancer Risk
Research shows that drinking coffee specifically reduces the risk of antiestrogen-resistant estrogen-receptor (ER)-negative breast cancer.
Wednesday, June 01, 2011
High Throughput RNAi Assay Optimization Using Adherent Cell Cytometry
Researchers from Harvard Medical School have detailed how adherent cell cytometry can be used as a high throughput-screening tool for the optimization of RNAi assays, accelerating in vitro cell assays and reducing costs.
Tuesday, May 03, 2011
Quantitative miRNA Expression Analysis Using Fluidigm Microfluidics Dynamic Arrays
An article published in the journal BMC Genomics demonstrates how the qPCR-array based microfluidic dynamic array platform can be used in conjunction with multiplexed RT reactions for miRNA gene expression profiling.
Tuesday, April 12, 2011
Scientific News
Nanocarriers May Carry New Hope for Brain Cancer Therapy
Berkeley lab researchers develop nanoparticles that can carry therapeutics across the brain blood barrier.
RNA-Based Drugs Give More Control Over Gene Editing
CRISPR/Cas9 gene editing technique can be transiently activated and inactivated using RNA-based drugs, giving researchers more precise control in correcting and inactivating genes.
University of Glasgow Researchers Make An Impact in 60 Seconds
Early-career researchers were invited to submit an engaging, dynamic and compelling 60 second video illuminating an aspect of their research.
Metabolic Profiles Distinguish Early Stage Ovarian Cancer with Unprecedented Accuracy
Studying blood serum compounds of different molecular weights has led scientists to a set of biomarkers that may enable development of a highly accurate screening test for early-stage ovarian cancer.
Dead Bacteria to Kill Colorectal Cancer
Scientists from Nanyang Technological University (NTU Singapore) have successfully used dead bacteria to kill colorectal cancer cells.
CRISPR-Cas9 Gene Editing: Check Three Times, Cut Once
Two new studies from UC Berkeley should give scientists who use CRISPR-Cas9 for genome engineering greater confidence that they won’t inadvertently edit the wrong DNA.
Genetically Engineering Algae to Kill Cancer Cells
New interdisciplinary research has revealed the frontline role tiny algae could play in the battle against cancer, through the innovative use of nanotechnology.
How to Control Shape, Structure of DNA and RNA
Researchers have used computational modelling to shed light on precisely how charged gold nanoparticles influence the structure of DNA and RNA.
Advancing Genome Editing of Blood Stem Cells
Genome editing techniques for blood stem cells just got better, thanks to a team of researchers at USC and Sangamo BioSciences.
Gene-Edited Immune Cells Treat ‘Incurable’ Leukaemia
A new treatment that uses ‘molecular scissors’ to edit genes and create designer immune cells programmed to hunt out and kill drug resistant leukaemia has been used at Great Ormond Street Hospital (GOSH).

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos